Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
125.93
-2.03 (-1.59%)
Apr 15, 2025, 3:01 PM EDT - Market open
Abbott Laboratories Revenue
In the year 2024, Abbott Laboratories had annual revenue of $41.95B with 4.59% growth. Abbott Laboratories had revenue of $10.97B in the quarter ending December 31, 2024, with 7.16% growth.
Revenue (ttm)
$41.95B
Revenue Growth
+4.59%
P/S Ratio
5.31
Revenue / Employee
n/a
Employees
n/a
Market Cap
218.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck & Co. | 64.17B |
Pfizer | 63.63B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Sanofi | 45.85B |
Thermo Fisher Scientific | 42.88B |
Novo Nordisk | 40.31B |
Danaher | 23.88B |
ABT News
- 6 hours ago - How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings - Benzinga
- 14 days ago - Best Dividend Aristocrats For April 2025 - Seeking Alpha
- 15 days ago - New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve - PRNewsWire
- 19 days ago - Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms - PRNewsWire
- 20 days ago - Abbott Hosts Conference Call for First-Quarter Earnings - PRNewsWire
- 22 days ago - Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease - PRNewsWire
- 25 days ago - 2025 Dividend Kings: Strong Run Continues - Seeking Alpha
- 4 weeks ago - Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees - Seeking Alpha